Forecasts data is unavailable for this security.

Consensus recommendation

As of Apr 21, 2017, the consensus forecast amongst 28 polled investment analysts covering GlaxoSmithKline plc advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Sep 13, 2016. The previous consensus forecast advised investors to hold their position in GlaxoSmithKline plc.
  • 1yr ago
  • 3M ago
  • 2M ago
  • 1M ago
  • Latest
Select bar for recommendation details.

Share price forecast

The 25 analysts offering 12 month price targets for GlaxoSmithKline plc have a median target of 1,800.00, with a high estimate of 2,200.00 and a low estimate of 1,300.00. The median estimate represents a 13.56% increase from the last price of 1,585.00.


In 2016, GlaxoSmithKline PLC reported a dividend of 0.80 GBP, equaling last years dividend. The 23 analysts covering the company expect dividends of 0.80 GBP for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates

On Feb 08, 2017, GlaxoSmithKline plc reported 4th quarter 2016 earnings of 0.261 per share. This result was in line with the consensus of the 11 analysts following the company and exceeded last year's 4th quarter results by 44.20%.
The next earnings announcement is expected on Apr 26, 2017.
Average growth rate+11.33%
GlaxoSmithKline plc reported annual 2016 earnings of 1.02 per share on Feb 08, 2017.
The next earnings announcement from GlaxoSmithKline plc is expected the week of Feb 05, 2018.
Average growth rate-0.19%
More ▼

Revenue history & estimates

GlaxoSmithKline plc had 4th quarter 2016 revenues of 7.59bn. This bettered the 7.44bn consensus of the 10 analysts covering the company. This was 20.68% above the prior year's 4th quarter results.
Average growth rate+5.00%
GlaxoSmithKline plc had revenues for the full year 2016 of 27.89bn. This was 16.58% above the prior year's results.
Average growth rate+1.91%
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.